Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Observations on a factor-V inhibitor.

E B Crowell

    British Journal of Haematology
    |March 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    A patient developed a potent factor V inhibitor after transfusions and surgery. This autoantibody, likely immunoglobulin G, targeted factor V, causing a rare bleeding disorder.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.

    The West Virginia medical journal·2001
    Same author

    The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.

    The West Virginia medical journal·2001
    Same author

    Severe, disabling neurologic toxicity following cisplatin retreatment.

    The Annals of pharmacotherapy·1995
    Same author

    Breast cancer--a medical disease?

    The West Virginia medical journal·1993
    Same author

    The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.

    The West Virginia medical journal·1993
    Same author

    The Breast Cancer Prevention Trial (BCPT) in West Virginia.

    The West Virginia medical journal·1992

    Area of Science:

    • Hematology
    • Immunology
    • Coagulation Science

    Background:

    • Acquired factor V inhibitors are rare but serious bleeding disorders.
    • They can arise spontaneously or be associated with various medical conditions, including autoimmune diseases, infections, and medications.

    Observation:

    • A 67-year-old male developed a potent inhibitor of factor V following blood transfusions and surgery.
    • The inhibitor exhibited time-dependent reactivity with factor V and a non-linear concentration-dependent inhibition pattern.
    • Immunochemical analysis revealed the inhibitor comprised gamma and mu heavy chains and both kappa and lambda light chains, consistent with an immunoglobulin G (IgG) or IgM antibody.

    Findings:

    • The patient's inhibitor demonstrated specific binding to factor V.
    • The inhibitor's characteristics suggested an autoimmune etiology.

    Related Experiment Videos

  • Plasma from patients with congenital factor V deficiency did not neutralize the inhibitor, ruling out cross-reactivity with a non-specific clotting factor or a contaminant.

    • Implications:

    • This case highlights the importance of considering acquired factor V inhibitors in patients presenting with unexplained bleeding, especially post-transfusion or post-surgery.
    • Understanding the immunochemical properties of such inhibitors is crucial for diagnosis and management.
    • Further research into the pathogenesis of acquired factor V inhibitors may lead to targeted therapies.